This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Dyslipidaemia: Focus shifts from LDL-C to HDL-C
ABSTRACT: In this current analysis of the antidyslipidaemics market, a shift in focus from low-density lipoprotein cholesterol (LDL-C)-targeted therapies to drugs that elevate high-density lipoprotein cholesterol (HDL-C) is described. Key reasons for this evolution are several-fold, but mainly focus on significant generic erosion of LDL-C-targeted therapies, particularly the statins, and loss of revenues therein...
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
- Management
- Policy
- Finance
- Law
- Regulation
- Bioethics
For more information, see the Journal of Commercial Biotechnology website